Iron Triangle Partners’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-850,000
Closed -$57.2M 32
2025
Q3
$57.2M Buy
+850,000
New +$67.3M 8.13% 2
2024
Q3
Sell
-582,199
Closed -$66M 31
2024
Q2
$66M Buy
582,199
+110,568
+23% +$14M 6.71% 2
2024
Q1
$65.4M Buy
471,631
+181,631
+63% +$22.8M 6.7% 2
2023
Q4
$36M Sell
290,000
-275,753
-49% -$28.2M 4.66% 9
2023
Q3
$52.8M Buy
565,753
+415,753
+277% +$46.9M 7.71% 3
2023
Q2
$19.3M Sell
150,000
-190,000
-56% -$23M 2.58% 17
2023
Q1
$39.5M Buy
340,000
+219,920
+183% +$24.6M 5.7% 4
2022
Q4
$13.6M Sell
120,080
-29,920
-20% -$3.28M 2.44% 18
2022
Q3
$12.1M Sell
150,000
-350,000
-70% -$29.6M 2.11% 25
2022
Q2
$37.3M Buy
500,000
+220,000
+79% +$20.1M 4.83% 7
2022
Q1
$35.8M Buy
+280,000
New +$30.6M 4.26% 10
2021
Q1
Sell
-300,000
Closed -$27.7M 29
2020
Q4
$27.7M Buy
+300,000
New +$26.8M 3.59% 13
2020
Q2
Sell
-80,000
Closed -$5.38M 27
2020
Q1
$5.38M Sell
80,000
-102,936
-56% -$6.41M 2.08% 22
2019
Q4
$10M Buy
+182,936
New +$8.68M 2.65% 21

Other funds holding DXCM

Iron Triangle Partners's DXCM Position: Q4 2025 in Review

Iron Triangle Partners sold out of DexCom (DXCM) in Q4 2025, closing a stake of 850,000 shares — an estimated $57.2M sold.

Iron Triangle Partners first reported a position in DXCM in Q4 2019 and held it in 14 quarters. The position peaked at $66M in Q2 2024. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

  • Iron Triangle Partners reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
  • Iron Triangle Partners sold 850,000 DexCom shares in Q4 2025, an estimated $57.2M.
  • Iron Triangle Partners first reported a position in DexCom in Q4 2019 and held it in 14 quarters.
  • Iron Triangle Partners's DexCom position peaked at $66M in Q2 2024.
  • 920 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.